MX2021004603A - Dosificacion. - Google Patents

Dosificacion.

Info

Publication number
MX2021004603A
MX2021004603A MX2021004603A MX2021004603A MX2021004603A MX 2021004603 A MX2021004603 A MX 2021004603A MX 2021004603 A MX2021004603 A MX 2021004603A MX 2021004603 A MX2021004603 A MX 2021004603A MX 2021004603 A MX2021004603 A MX 2021004603A
Authority
MX
Mexico
Prior art keywords
human
administering
dosing
antagonist
dose
Prior art date
Application number
MX2021004603A
Other languages
English (en)
Inventor
Patrick Mayes
Elaine Marie Paul
Catherine E Ellis
Jessica Katz
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2021004603A publication Critical patent/MX2021004603A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a un método de tratamiento de cáncer en un humano en necesidad del mismo, el método comprende administrar al humano una proteína agonista de unión a ICOS o porción de unión a antígeno de la misma a una dosis de cerca de 0.08 5 mg a cerca de 240 mg y administrar al humano un antagonista de PD1.
MX2021004603A 2018-10-22 2019-10-21 Dosificacion. MX2021004603A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862748595P 2018-10-22 2018-10-22
US201962807897P 2019-02-20 2019-02-20
US201962837385P 2019-04-23 2019-04-23
US201962895229P 2019-09-03 2019-09-03
US201962902444P 2019-09-19 2019-09-19
PCT/US2019/057251 WO2020086476A1 (en) 2018-10-22 2019-10-21 Dosing

Publications (1)

Publication Number Publication Date
MX2021004603A true MX2021004603A (es) 2021-09-08

Family

ID=68542765

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004603A MX2021004603A (es) 2018-10-22 2019-10-21 Dosificacion.

Country Status (9)

Country Link
US (1) US20210324081A1 (es)
EP (2) EP3870220A1 (es)
JP (2) JP2022505524A (es)
CN (2) CN113226369A (es)
AU (1) AU2019366321A1 (es)
BR (2) BR112021007517A2 (es)
CA (2) CA3116584A1 (es)
MX (1) MX2021004603A (es)
WO (2) WO2020086479A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230504A1 (en) * 2022-05-25 2023-11-30 Xencor, Inc. Methods for treating solid tumors using icos x pd-1 bispecific antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
RU2549701C2 (ru) 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
EP3590969A1 (en) 2011-03-31 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2014033327A1 (en) 2012-09-03 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos for treating graft-versus-host disease
EP2903641A2 (en) 2012-10-04 2015-08-12 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
SI3273992T1 (sl) 2015-03-23 2020-09-30 Jounce Therapeutics, Inc. Protitelesa proti ICOS
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
MX2016016208A (es) 2016-09-13 2018-06-06 Tupy S A Aleacion de hierro fundido vermicular y culata de motor de combustion interna.
US11884738B2 (en) * 2017-03-31 2024-01-30 The University Of North Carolina At Chapel Hill Methods and compositions for activation of T cells using nanoparticles conjugated with multiple ligands for binding receptors on T cells
WO2018187191A1 (en) * 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途

Also Published As

Publication number Publication date
JP2022513374A (ja) 2022-02-07
WO2020086476A1 (en) 2020-04-30
CA3117746A1 (en) 2020-04-30
CN113226369A (zh) 2021-08-06
EP3870219A1 (en) 2021-09-01
EP3870220A1 (en) 2021-09-01
JP2022505524A (ja) 2022-01-14
BR112021007517A2 (pt) 2021-10-26
WO2020086479A1 (en) 2020-04-30
CA3116584A1 (en) 2020-04-30
AU2019366321A1 (en) 2021-05-13
CN113453715A (zh) 2021-09-28
BR112021007082A2 (pt) 2021-08-03
US20210324081A1 (en) 2021-10-21
WO2020086479A9 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2020011546A (es) Anticuerpos anti-msr1 y metodos de uso de los mismos.
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
MX2020010144A (es) Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38).
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
MX2016008362A (es) Combinaciones farmaceuticas.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
CR20210272A (es) Anticuerpos humanizados contra c-kit
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
MX2020009468A (es) Terapias de combinacion de agonistas de 4-1bb con anticuerpos anti-cd20.
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
NZ762312A (en) Anti-pacap antibody
MX2021004603A (es) Dosificacion.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2019011958A (es) Proteína de fusión activadora de células nk, célula nk, y composición farmacéutica que las incluye.
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
EP4076482A4 (en) COMPOSITIONS FOR MODULATING INTESTINAL MICROFLORA POPULATIONS, IMPROVING THE EFFECTIVENESS OF DRUGS AND TREATING CANCER, AND METHODS FOR THE PRODUCTION AND USE OF THE SAME
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof